Repligen (NASDAQ:RGEN) Shares Gap Up Following Strong Earnings

Repligen Corporation (NASDAQ:RGEN) gapped up before the market opened on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $131.06, but opened at $139.70. Repligen shares last traded at $151.4970, with a volume of 271,811 shares changing hands.

The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same period in the prior year, the business earned $0.26 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS.

More Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen delivered Q2 revenue of $204.1 million, up 11.9% year over year and above the $201.6 million consensus estimate. Organic revenue growth was 13%, reflecting continued order momentum and sequential improvement. Repligen Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Adjusted diluted EPS was $0.54, exceeding the $0.45 analyst consensus and rising from $0.37 a year earlier. Adjusted operating income increased 55% to $34 million, while adjusted operating margin expanded to 16.7% from 12.0%. Repligen Quarterly Earnings Results
• Positive Sentiment: Management raised full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, above the approximately $2.00 consensus EPS forecast. Total reported revenue is expected to reach $813 million-$835 million. Repligen Raises Full-Year Guidance
• Positive Sentiment: Repligen announced a definitive agreement to acquire BioLife Solutions, a deal management expects to strengthen its cell-therapy position and contribute to revenue growth, margins and adjusted EPS. The company ended June with $810 million in cash, cash equivalents and marketable securities, supporting financial flexibility.
• Neutral Sentiment: Investors must distinguish the adjusted results from GAAP results: GAAP diluted EPS fell to $0.09 from $0.26, while net income declined to $5.0 million from $14.9 million. The difference was driven largely by acquisition, restructuring, transformation, amortization and other items.
• Negative Sentiment: GAAP net margin dropped to 2.5% from 8.2%, and GAAP operating margin edged down to 6.8% from 7.6%. These figures may temper enthusiasm, particularly given RGEN’s elevated valuation, including a reported price-to-earnings ratio above 145.
• Negative Sentiment: The BioLife Solutions transaction remains subject to completion and integration risks, while recent insider activity cited in the coverage showed two sales and no purchases over the past six months.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RGEN. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Jefferies Financial Group restated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. HSBC dropped their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Canaccord Genuity Group reduced their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.36.

Insider Activity

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Institutional investors have recently made changes to their positions in the stock. Bayforest Capital Ltd bought a new position in shares of Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen in the fourth quarter valued at approximately $33,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Repligen during the third quarter valued at approximately $29,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen during the fourth quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC raised its position in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 15.3%

The company has a market capitalization of $8.52 billion, a P/E ratio of 168.05, a PEG ratio of 2.54 and a beta of 1.06. The business has a fifty day moving average of $132.21 and a 200-day moving average of $132.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.